Moreover, the most recent data showed that PEComa patients harboring TSC2 mutations and treated with mTOR inhibitors have a better ORR and PFS as compared to those with TSC1 mutations. This evidence concerns the gene TSC2 and neoplasm with perivascular epithelioid cell differentiation.